Sevval Arduc

Dr. Sevval Arduc

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 January 2024 in Antibiotics
Verified
Journal Article
Open access
PDF file
Okan DerinOkan Derin
Okan Derin
MSMeyha Sahin
Meyha Sahin
RDRıdvan Dumlu
Rıdvan Dumlu
SBSedef Başgönül
Sedef Başgönül
ABAhmet Doğukan BAYRAK
Ahmet Doğukan BAYRAK
AMAli Mert
Ali Mert
Background: Managing Pseudomonas aeruginosa bloodstream infections (BSIs) is challenging due to increasing antimicrobial resistance, limited therapeutic options, and high mortality rates. In this study, we aimed to identify 30-day mortality risk factors and assess infectious diseases consultants’ preferences for combination or monotherapy. Methods: The study was conducted in four hospitals in Istanbul, Turkey, involving 140 adult ICU beds and 336,780 ICU-bed-days between 1 January 2014, and 31 December 2021. A total of 157 patients were included in the study. Cox proportional hazard regression was performed to assess the factors on 30-day mortality. Results: The 30-day mortality rate was 44.6% (70/157). Higher Charlson Comorbidity Index (CCI) score, severe sepsis, primary bloodstream infection, being in COVID-19 pandemic period, and infection caused by MDR strain were associated with higher hazard of 30-day mortality. Combination therapy was more commonly used in patients with BSIs with MDR or DTR (difficult-to-treat) strains but did not significantly improve the hazard of 30-day mortality. Conclusions: Targeted interventions and vigilant management strategies are crucial for patients with defined risk factors. While infectious disease consultants tended to favor combination therapy, particularly for drug-resistant strains, our analysis revealed no significant impact on 30-day mortality hazard. The increased incidence of P. aeruginosa BSIs during the pandemic emphasizes the need for infection control measures and appropriate antibiotic prescribing practices.

24 July 2026 in Microbial Drug Resistance
Verified
Journal Article
Closed access
SASevval Arduc
Sevval Arduc
LGLeyla Genç
Leyla Genç
ABAyşe Barış
Ayşe Barış
EAElif Aktaş
Elif Aktaş
Since their first identification in Türkiye in 2001, OXA-48-like carbapenemases have posed diagnostic challenges due to variant-specific phenotypic and resistance profiles. We investigated the distribution of OXA-48 variants and their association with antimicrobial susceptibility, carbapenem minimum inhibitory concentrations (MICs), phenotypic detection performance, and single- or dual-carbapenemase production. A total of 703 clinical carbapenem-resistant Enterobacterales isolates recovered over 5 years were included. Identification and antimicrobial susceptibility testing were performed by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS) and an automated system; carbapenem MICs by broth microdilution; carbapenemase genes by multiplex qPCR; and OXA-48 variants by sequence analysis. CNPt-direct and mCIM were performed for OXA-48 variants. OXA-48-like, NDM, and KPC carbapenemases were detected in 52.3%, 11.7%, and 11.5% of isolates, respectively, with co-production observed in 11.7% of OXA-48-like–positive isolates. The most common OXA-48 variants were OXA-48/245 (39.1%), OXA-232 (36.4%), and OXA-181 (17.6%), while OXA-244, OXA-162, and OXA-1200 were less frequent. This study represents the first report of the OXA-1200 variant from Türkiye. OXA-48/245 was the variant most commonly co-produced with other carbapenemases, whereas OXA-244 predominated among CNPt-direct–negative isolates. Susceptibility to meropenem and imipenem among OXA-48-like producers was 31% and 39.1%, respectively, with higher carbapenem MIC 50 values observed for OXA-181, OXA-232, and OXA-48/245 compared to OXA-244. In K. pneumoniae , meropenem resistance rates were higher with OXA-48/245, OXA-232, and OXA-181 than with other variants. MIC 50 values of carbapenem were higher in dual carbapenemase producers compared to single carbapenemase producers. Our findings show that OXA-48 variants significantly impact resistance profiles, MIC values, and the sensitivity of phenotypic tests and detection of co-produced carbapenemases. Understanding their regional distribution is crucial for targeted prevention strategies.

11 November 2026 in European Journal of Clinical Microbiology & Infectious Diseases
Verified
Journal Article
Closed access
PDF file
LGLEYLA GENÇ
LEYLA GENÇ
IÜİrEm Zafer Üs
İrEm Zafer Üs
SASevval Arduc
Sevval Arduc
ÖGözlem Gül
özlem Gül
HTHanife Tutan
Hanife Tutan
EAElif Aktaş
Elif Aktaş